Related Experiment Video

Updated: Aug 5, 2025

Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling
11:19

Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling

Published on: November 17, 2019

16.2K

Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases

Yuping Yang1, Xiaoxiao Fan1, Yongjian Liu1

  • 1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.

Biochemical Pharmacology
|March 29, 2023
PubMed

Insights

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is crucial in disease development. This review covers DYRK1A

Area of Science:

  • Biochemistry and Molecular Biology
  • Cell Signaling
  • Disease Pathogenesis

Background:

  • Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a key protein kinase involved in numerous cellular processes.
  • Aberrant DYRK1A expression, either low or high, is linked to the pathogenesis of various diseases.
  • DYRK1A is recognized as a significant therapeutic target for multiple disorders.

Purpose of the Study:

  • To provide a comprehensive review of DYRK1A.
  • To elucidate the structure, function, and disease relevance of DYRK1A.
  • To summarize the landscape of DYRK1A inhibitors.

Main Methods:

  • Literature review of existing research on DYRK1A.
  • Analysis of studies detailing DYRK1A's role in disease.
  • Compilation of data on natural and synthetic DYRK1A inhibitors.

Main Results:

  • DYRK1A's involvement in diabetes mellitus, neurodegenerative diseases, and cancers is detailed.
  • The review categorizes and discusses various natural and synthetic DYRK1A inhibitors.
  • Structure-function relationships and disease mechanisms associated with DYRK1A are explored.

Conclusions:

  • DYRK1A is a critical regulator implicated in diverse pathologies.
  • Targeting DYRK1A with inhibitors presents a promising therapeutic strategy.
  • Further research into DYRK1A inhibitors is warranted for disease treatment.
Keywords:
CancersDYRK1ADiabetesInhibitorsNeurological diseases

More Related Videos

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.4K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K